Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Journal of Pharmacology

• Publication date

  2014-04-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2014.01.052PMID 24486705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro pharmacological profile of the A2A receptor antagonist istradefylline

  2013cited by this paper
• Neuroprotection afforded by adenosine A2A receptor blockade is modulated by corticotrophin‐releasing factor (CRF) in glutamate injured cortical neurons

  2012cited by this paper
• Adenosine A2A Antagonists in Parkinson’s Disease: What’s Next?

  2012cited by this paper
• A Potent and Selective Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator Improves Movement in Rodent Models of Parkinson's Disease

  2012cited by this paper
• Future Treatments for Parkinson's Disease: Surfing the PD Pipeline

  2011cited by this paper
• Pramipexole for the treatment of early Parkinson’s disease

  2011cited by this paper
• Design and Synthesis of Novel Dual‐Action Compounds Targeting the Adenosine A2A Receptor and Adenosine Transporter for Neuroprotection

  2011cited by this paper
• Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease

  2011cited by this paper
• Adenosine A2A Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease

  2011cited by this paper
• Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.

  2010cited by this paper
• MitoPark mice mirror the slow progression of key symptoms and L‐DOPA response in Parkinson's disease

  2010cited by this paper
• A2A adenosine receptor overexpression and functionality, as well as TNF‐α levels, correlate with motor symptoms in Parkinson's disease

  2010cited by this paper
• Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice.

  2010cited by this paper
• Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease.

  2010cited by this paper
• The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.

  2009cited by this paper
• Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

  2009cited by this paper
• The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates

  2008cited by this paper
• Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.

  2007cited by this paper
• The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors.

  2007cited by this paper
• Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease

  2007cited by this paper
• Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.

  2007cited by this paper
• Adenosine A2A antagonists as neurotherapeutics: crossing the bridge.

  2007cited by this paper
• Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.

  2007cited by this paper
• Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease.

  2007cited by this paper
• Adenosine receptors as therapeutic targets

  2006cited by this paper
• Alternatives to Levodopa in the Initial Treatment of Early Parkinson’s Disease

  2005cited by this paper
• Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.

  2004cited by this paper
• Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender.

  2004cited by this paper
• Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD

  2003cited by this paper
• Involvement of Adenosine A1 and A2A Receptors in the Motor Effects of Caffeine after its Acute and Chronic Administration

  2003cited by this paper
• Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa‐induced motor complications

  2003cited by this paper
• Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum

  2001cited by this paper
• Decreased pallidal GABA following reverse microdialysis with clozapine, but not haloperidol

  2001cited by this paper
• Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6‐hydroxydopamine‐lesioned rats

  2001cited by this paper
• Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist.

  2000cited by this paper
• Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.

  2000cited by this paper
• Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.

  2000cited by this paper
• Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

  1999cited by this paper

• A2AR antagonist IDPU facilitates the restoration of mitochondrial dynamics in 6-OHDA-induced primary mid-brain neuronal cells, via regulating p38MAPK/Parkin/DJ-1/DRP1 axis

  2026cites this paper
• ESTUDO COMPUTACIONAL DA CAFEÍNA COMO BASE PARA A CONSTRUÇÃO DE POSSÍVEIS INIBIDORES DE RECEPTORES ASSOCIADOS À DOENÇA DE PARKINSON

  2025cites this paper
• Morphological and functional decline of the SNc in a model of progressive parkinsonism

  2025cites this paper
• Purinergic-associated immune responses in neurodegenerative diseases.

  2024cites this paper
• Effects of the adenosine A2A receptor antagonist KW6002 on the dopaminergic system, motor performance, and neuroinflammation in a rat model of Parkinson's disease.

  2024cites this paper
• A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists.

  2023cites this paper
• Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.

  2021cites this paper
• A Critical Analysis of Quercetin as the Attractive Target for the Treatment of Parkinson's Disease.

  2021cites this paper
• Reduction in murine acute GVHD severity by human gingival tissue-derived mesenchymal stem cells via the CD39 pathways

  2019cites this paper
• Tumor-Induced Immunosuppression T Cells from + Tumor-Reactive CD 8 Antagonist Liberate 2 ASynthetic A Adenosine Receptor Gene Deletion or 2 AA

  2018cites this paper
• A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression

  2018cites this paper
• Control of Motor Function by Adenosine A2A Receptors in Parkinson's and Huntington's Disease

  2017cites this paper
• Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease

  2017cites this paper
• Adenosine A 2A Receptor Antagonists as Drugs for Symptomatic Control of Parkinson’s Disease in Preclinical Studies

  2015influential citation
• Adenosine A2A Receptor-Mediated Control of Non-Motor Functions in Parkinson’s Disease

  2015cites this paper
• Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease

  2015cites this paper